Agenda Released for 19th Annual Superbugs European Show with Keynotes from FDA, BARDA and GSK

LONDON - Nov. 2, 2016 - PRLog -- Following on from what is set to be a successful Superbugs USA summit in two weeks' time, SMi Group is delighted to release an agenda for its 19th annual Superbugs & Superdrugs European conference which returns to Central London on 20th and 21st March 2017.

London's flagship show in the global Superbugs portfolio of events has been expanding horizons on the growing threat of anti-microbial resistance (AMR) and infectious disease for almost two decades. It will once again provide a focal point for its growing "superbugs" community comprising of scientific leaders, funding bodies and drug discovery specialists, to network, exchange novel solutions and consolidate current strategies.

The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered by a panel of speakers who will hone in on key issues such as industry funding opportunities, the use of animal models in drug research and antimicrobial peptides.

Highlights will include a special regulatory spotlight on antibacterial drug development presented by Sumathi Nambiar, Director of the FDA Division of Anti-Infective Products.

Conference Chairmen, Richard Bax, Senior Partner from TranScrip; and Lloyd Czaplewski, Director of Chemical Biology Ventures said in a joint statement:

"In 2016 antimicrobial resistance achieved remarkable global attention. For a decade the community talked about the need for industry, academia and government to act on an international level to address the scientific challenges of antibiotic discovery, diagnosis, addressing the economics of antibiotics and to invest in unprecedented ways. In 2016 we may have witnessed change… Networking and learning with our peers is the secret to improving the drug development pipeline."

Other notable speakers on the agenda for Superbugs & Superdrugs 2017 include:

Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GSK
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, CEO, Discuva
Martin Everett, CSO, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Dir, Pre-Clinical Services, UNT System College of Pharmacy

Further details including a full speaker line-up and detailed programme are available at http://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-...

For those looking to register, there is currently a £400 early bird saving available online which expires on 30th November 2016.

Superbugs & Superdrugs 2017
20th & 21st March,
Copthorne Tara Hotel, London UK

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For delegate enquires contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About Superbugs USA:

Superbugs and Superdrugs USA will take place on 14th & 15th November 2016 in Iselin, New Jersey.
Further information is available at http://www.smi-online.co.uk/pharmaceuticals/northamerica/...

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk